Keyphrases
Serious Complications
100%
Tumor Lysis Syndrome
100%
Radioligand Therapy
100%
Prostate Cancer
28%
Tumor Cancer
28%
Neuroendocrine Tumor
28%
Clinical Characteristics
14%
Partial Remission
14%
Prostate-specific Antigen
14%
Appropriate Treatment
14%
Laboratory Abnormalities
14%
Characteristic Changes
14%
Progressive Disease
14%
Clinical Symptoms
14%
Safe Treatment
14%
Lutetium-177 (177Lu)
14%
Laboratory Parameters
14%
Patient Monitoring
14%
Clinical Abnormalities
14%
Labeled Peptide
14%
Metastasizing
14%
Patient Database
14%
Start of Treatment
14%
Symptom Change
14%
DOTATOC
14%
177Lu-DOTATATE
14%
Mixed Response
14%
Pharmacology, Toxicology and Pharmaceutical Science
Radioligand
100%
Tumor Lysis Syndrome
100%
Prostate Cancer
28%
Neuroendocrine Tumor
28%
Lutetium 177
28%
Remission
14%
Prostate Specific Membrane Antigen
14%
Diseases
14%